Exhibit 10.3
Form of H3 CVR
Agreement
CONTINGENT VALUE RIGHTS
AGREEMENT
THIS CONTINGENT VALUE RIGHTS
AGREEMENT , dated as of
[ —
], 2009 (this “
Agreement” , is entered into by and among
Ligand Pharmaceuticals Incorporated, a Delaware corporation
(“ Buyer ”), Neurogen Corporation, a
Delaware corporation (“ Target ”), and
[ —
], a [
—
], as Rights Agent (the
“ Rights Agent ”) and as initial H3 CVR
Registrar (as defined herein).
Preamble
Buyer, Neon Signal, LLC, a Delaware
limited liability company and wholly-owned subsidiary of Buyer
(“ Sub ”), and Target have entered into
an Agreement and Plan of Merger dated as of August 23, 2009
(the “ Merger Agreement ”), pursuant to
which Sub will merge with and into Target (the “
Merger ”), with Target surviving the Merger as
a subsidiary of Buyer.
Pursuant to the Merger Agreement,
Buyer agreed to create and issue to Target’s stockholders of
record immediately before the effective time of the Merger,
contingent value rights as hereinafter described.
The parties have done all things
necessary to make the contingent value rights, when issued pursuant
to the Merger Agreement and hereunder, the valid obligations of
Buyer and to make this Agreement a valid and binding agreement of
Buyer, in accordance with its terms.
NOW, THEREFORE, for and in
consideration of the premises and the consummation of the
transactions referred to above, it is mutually covenanted and
agreed, for the equal and proportionate benefit of all Holders (as
hereinafter defined), as follows:
ARTICLE I
DEFINITIONS
Section 1.1.
Definitions .
(a) For all purposes of this
Agreement, except as otherwise expressly provided or unless the
context otherwise requires:
(i) the terms defined in this
Article have the meanings assigned to them in this Article, and
include the plural as well as the singular;
(ii) all accounting terms used
herein and not expressly defined herein shall have the meanings
assigned to such terms in accordance with United States generally
accepted accounting principles, as in effect on the date
hereof;
(iii) the words
“herein,” “hereof’ and
“hereunder” and other words of similar import refer to
this Agreement as a whole and not to any particular Article,
Section or other subdivision;
(iv) unless the context otherwise
requires, words describing the singular number shall include the
plural and vice versa, words denoting any gender shall include all
genders and words denoting natural Persons shall include
corporations, partnerships and other Persons and vice versa;
and
(v) all references to
“including” shall be deemed to mean including without
limitation.
(b) Capitalized terms used but not
otherwise defined herein shall have the meanings ascribed thereto
in the Merger Agreement. The following terms shall have the
meanings ascribed to them as follows:
“ Achievement
Certificate ” has the meaning set forth in
Section 2.4(a).
“ Board of Directors
” means the board of directors of Buyer.
“ Board Resolution
” means a copy of a resolution certified by the secretary or
an assistant secretary of Buyer to have been duly adopted by the
Board of Directors and to be in full force and effect on the date
of such certification, and delivered to the Rights
Agent.
“ Business Day ”
means any day other than a Saturday, Sunday or a day on which
banking institutions in New York, New York are authorized or
obligated by law or executive order to remain closed.
“ Holder ” means
a Person in whose name a H3 CVR is registered in the H3 CVR
Register.
“ H3 Antagonist Program
” means the antagonist program conducted before the Merger by
Target intended to create an H3 receptor drug, and as may be
continued after the Merger by Buyer.
“ H3 CVR Payment Amount
” means, as applicable, an H3 Licensing Option Payment
Amount, an H3 Sale Option Payment Amount, the H3 Licensing Payment
or the H3 Sale Payment Amount (together with any H3 Licensing
Option Payment Amount). For purposes of clarity, the Holders shall
only be entitled to either the H3 Licensing Payment or the H3 Sale
Payment Amount (together with any H3 Licensing Option Payment
Amount), or neither of them, but in no circumstances
both.
“ H3 CVR Payment Date
” means the date (if any and if ever) that an H3 CVR Payment
Amount is payable by Buyer to the Holders, which date shall be
established pursuant to Section 2.4.
“ H3 CVR Payment Event
” means, as applicable, an H3 Licensing Option Event, an H3
Licensing Event, an H3 Sale Option Event or an H3 Sale
Event.
“ H3 CVR Register
” has the meaning set forth in
Section 2.3(b).
“ H3 CVR Registrar
” has the meaning set forth in
Section 2.3(b).
“ H3 CVRs ” means
the H3 Contingent Value Rights issued by Buyer pursuant to the
Merger Agreement and this Agreement.
“ H3 Licensing Event
” means the licensing (but not to include a license in a
transaction which includes no royalty nor milestone payments) by
Buyer to any Person (other than to Buyer) of a drug candidate or
technology or Intellectual Property from the H3 Antagonist
Program.
2
“ H3 Licensing Option
Event ” means the grant of an option by Buyer to any
Person (other than Buyer) to enter into an H3 Licensing
Event.
“ H3 Licensing Option
Payment Amount ” means an amount equal to 50% of the
aggregate cash proceeds actually received by Buyer, or any of its
subsidiaries or Affiliates, after the Effective Time and prior to
the Outside Date, in connection with an H3 Licensing Option Event,
less any costs and expenses reasonably incurred by Buyer, or any of
its subsidiaries or Affiliates, in connection with the H3 Licensing
Option Event (including attorneys fees and brokers
commissions).
“ H3 Licensing Payment
” means, in the event of an H3 Licensing Event, an aggregate
amount equal to $4,000,000 in cash less any H3 Licensing Option
Payment Amount.
“ H3 Sale Event ”
means the consummation of the sale or other similar transfer (that
does not qualify as a H3 Licensing Event) by Buyer to any Person
(other than Buyer) of a drug candidate or technology or
Intellectual Property from the H3 Antagonist Program.
“ H3 Sale Option Event
” means the grant of an option by Buyer to any Person (other
than Buyer) to enter into a H3 Sale Event.
“ H3 Sale Option Payment
Amount ” means an amount equal to 50% of the aggregate
cash proceeds actually received by Buyer, or any of its
subsidiaries or Affiliates, after the Effective Time and prior to
the Outside Date, in connection with an H3 Sale Option Event, less
any costs and expenses reasonably incurred by Buyer, or any of its
subsidiaries or Affiliates, in connection with the H3 Sale Option
Event (including attorneys fees and brokers
commissions).
“ H3 Sale Payment
Amount ” means an amount equal to 50% of the aggregate
cash proceeds actually received by Buyer, or any of its
subsidiaries or Affiliates, after the Effective Time and prior to
the Outside Date, in connection with an H3 Sale Event, less any
costs and expenses reasonably incurred by Buyer, or any of its
subsidiaries or Affiliates, in connection with the H3 Sale Event
(including attorneys fees and brokers commissions).
“ Non-Achievement
Certificate ” has the meaning set forth in
Section 2.4(b).
“ Notice of Objection
” has the meaning set forth in
Section 2.4(d).
“ Objection Period
” has the meaning set forth in
Section 2.4(d).
“ Officer’s
Certificate ” means a certificate signed by the chief
executive officer, president, chief financial officer, any vice
president, the controller, the treasurer or the secretary, in each
case, of Buyer, in his or her capacity as such an officer, and
delivered to the Rights Agent.
“ Outside Date ”
means [insert date that is three years from the Effective Date];
provided, that if pursuant to the preceding subsections the Outside
Date has not already occurred by the H3 Licensing Event, then the
Outside Date shall mean immediately after the H3 Licensing Event;
and provided further, that in the event of an H3 Licensing Option
Event or an H3 Sale Option Event, the Outside Date shall not occur
before the earliest of the exercise, expiration or termination of
such option.
“ Permitted Transfer
” means: (i) the transfer of any or all of the H3 CVRs
(upon the death of the Holder) by will or intestacy;
(ii) transfer by instrument to an inter vivos or testamentary
trust in which the H3 CVRs are to be passed to beneficiaries upon
the
3
death of the trustee; (iii) transfers made
pursuant to a court order of a court of competent jurisdiction
(such as in connection with divorce, bankruptcy or liquidation);
(iv) if the Holder is a partnership or limited liability
company, a pro-rata distribution by the transferring partnership or
limited liability company to its partners or members, as
applicable; (v) a transfer made by operation of law (including
a consolidation or merger) or in connection with the dissolution,
liquidation or termination of any corporation, limited liability
company, partnership or other entity; (vi) a transfer from a
participant’s account in a tax-qualified employee benefit
plan to the participant or to such participant’s account in a
different tax-qualified employee benefit plan or to a tax-qualified
individual retirement account for the benefit of such participant;
or (vii) a transfer from a participant in a tax-qualified
employee benefit plan, who received the H3 CVRs from such
participant’s account in such tax-qualified employee benefit
plan, to such participant’s account in a different
tax-qualified employee benefit plan or to a tax-qualified
individual retirement account for the benefit of such
participant.
“ Person ” means
any natural person, corporation, partnership, limited liability
company, trust, estate, other firm or entity, or governmental
body.
“ Rights Agent ”
means the Rights Agent named in the first paragraph of this
Agreement, until a successor Rights Agent shall have become such
pursuant to the applicable provisions of this Agreement, and
thereafter “Rights Agent” shall mean such successor
Rights Agent.
“ Rights Agent Fee
” means the agreed-upon fee of the Rights Agent to act in
such capacity pursuant to the terms of this Agreement.
“ Surviving Person
” has the meaning set forth in
Section 6.1(a)(i).
ARTICLE II
CONTINGENT VALUE
RIGHTS
Section 2.1. Issuance of H3
CVRs; Appointment of Rights Agent .
(a) The H3 CVRs shall be issued
pursuant to the Merger Agreement at the time and in the manner set
forth in the Merger Agreement.
(b) Buyer hereby appoints
[ —
] as the Rights Agent to act
as rights agent for Buyer in accordance with the instructions
hereinafter set forth in this Agreement, and the Rights Agent
hereby accepts such appointment.
Section 2.2.
Nontransferable .
The H3 CVRs shall not be sold,
assigned, transferred, pledged, encumbered or in any other manner
transferred or disposed of, in whole or in part, other than through
a Permitted Transfer.
Section 2.3. No Certificate;
Registration; Registration of Transfer; Change of
Address .
(a) The H3 CVRs shall not be
evidenced by a certificate or other instrument.
(b) The Rights Agent shall keep a
register (the “ H3 CVR Register ”) for
the registration of H3 CVRs. The Rights Agent is hereby initially
appointed “ H3 CVR Registrar ” for the
purpose of registering H3 CVRs and transfers of H3 CVRs as herein
provided. Upon any change in the identity of the Rights Agent, the
successor Rights Agent shall automatically also become the
successor H3 CVR Registrar.
4
(c) Subject to the restriction on
transferability set forth in Section 2.2, every request made
to transfer a H3 CVR must be in writing and accompanied by a
written instrument or instruments of transfer and any other
requested documentation in a form reasonably satisfactory to Buyer
and the H3 CVR Registrar, duly executed by the registered Holder or
Holders thereof or by the duly appointed legal representative
thereof or by a duly authorized attorney, such signature to be
guaranteed by a participant in a recognized Signature Guarantee
Medallion Program. A request for a transfer of a H3 CVR shall be
accompanied by such documentation establishing that the transfer is
a Permitted Transfer as may be reasonably requested by Buyer and/or
the H3 CVR Registrar (including opinions of counsel), if
appropriate. Upon receipt of such written request and materials,
the H3 CVR Registrar shall, subject to its reasonable determination
that the transfer instrument is in proper form and the transfer
otherwise complies with the other terms and conditions herein,
register the transfer of the H3 CVRs in the H3 CVR Register. All
duly transferred H3 CVRs registered in the H3 CVR Register shall be
the valid obligations of Buyer, evidencing the same right and shall
entitle the transferee to the same benefits and rights under this
Agreement, as those previously held by the transferor. No transfer
of a H3 CVR shall be valid until registered in the H3 CVR Register,
and any transfer not duly registered in the H3 CVR Register will be
void ab initio. Any transfer or assignment of the H3 CVRs shall be
without charge (other than the cost of any transfer tax which shall
be the responsibility of the transferor) to the Holder.
(d) A Holder may make a written
request to the H3 CVR Registrar to change such Holder’s
address of record in the H3 CVR Register. The written request must
be duly executed by the Holder. Upon receipt of such written
notice, the H3 CVR Registrar shall promptly record the change of
address in the H3 CVR Register.
Section 2.4. Payment
Procedures .
(a) Promptly following the
occurrence of an H3 CVR Payment Event, but in no event later than
five Business Days after the occurrence of an H3 CVR Payment Event,
Buyer shall deliver to the Rights Agent a certificate (the “
Achievement Certificate ”), certifying that the
Holders are entitled to receive an H3 CVR Payment Amount. No
transaction described in Section 6.1(a) hereof shall give the
Holders the right to receive an H3 CVR Payment Amount.
(b) If any H3 CVR Payment Event has
not occurred on or before the Outside Date, then, within five
Business Days after the Outside Date, Buyer shall deliver to the
Rights Agent a certificate (the “ Non-Achievement
Certificate ”), stating that the H3 CVR Payment Event
did not occur.
(c) Except as otherwise requested by
any Holder, the Rights Agent shall promptly (and in no event later
than five Business Days after receipt thereof) send each Holder a
copy of any Achievement Certificate or Non-Achievement Certificate
at its registered address.
(d) Upon demand by any Holder or
Holders of at least 20% in the aggregate of the outstanding H3 CVRs
within 45 calendar days after distribution by the Rights Agent
of a Non-Achievement Certificate (the “ Objection
Period ”), the Rights Agent shall deliver a written
notice to Buyer prepared by such Holder or Holders specifying that
such Holder or Holders object to the
5
determination of Buyer that the H3 CVR Payment
Event did not occur (a “ Notice of Objection
”) and stating the reason upon which such Holder or Holders
have determined that the H3 CVR Payment Event has occurred on or
before the Outside Date. Any dispute arising from a Notice of
Objection shall be resolved in accordance with the procedure set
forth in Section 7.12, which decision shall be binding on the
parties hereto and every Holder (including the Holders not
participating therein).
(e) If a Notice of Objection has not
been delivered to Buyer within the Objection Period, then the
Holders shall have no right to receive the H3 CVR Payment Amount,
and Buyer and the Rights Agent shall have no further obligations
with respect to the H3 CVR Payment Amount.
(f) If Buyer delivers an Achievement
Certificate to the Rights Agent or if the H3 CVR Payment Amount is
determined to be payable pursuant to Section 2.4(d) above,
Buyer shall establish a H3 CVR Payment Date that is within 15
calendar days after the date of the Achievement Certificate or the
date of final determination pursuant to Section 2.4(d) above,
as applicable. At least five Business Days before such H3 CVR
Payment Date, Buyer shall cause the H3 CVR Payment Amount to be
delivered to the Rights Agent, who will in turn, on the H3 CVR
Payment Date, distribute the H3 CVR Payment Amount to the Holders
(each Holder being entitled to receive its pro rata share of
the H3 CVR Payment Amount based on the number of H3 CVRs held (as
of the date of the Achievement Certificate or the date of final
determination pursuant to Section 2.4(d) above, as applicable)
by such Holder as reflected on the H3 CVR Register) (i) by
check mailed to the address of each such respective Holder as
reflected in the H3 CVR Register as of the close of business on the
last Business Day before such H3 CVR Payment Date, or,
(ii) with respect to any Holder that is due payment pursuant
to this Agreement in excess of $1,000,000 who has provided the
Rights Agent with wire transfer instructions, by wire transfer of
immediately available funds to such account.
(g) Buyer